tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NVCT Stock Latest News

Nuvectis Pharma initiates NXP900 program
The FlyNuvectis Pharma initiates NXP900 program
1M ago
NVCT
Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments
PremiumRatings
Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments
1M ago
NVCT
Nuvectis Pharma Reports Q2 2025 Financial Results and Progress
PremiumCompany Announcements
Nuvectis Pharma Reports Q2 2025 Financial Results and Progress
1M ago
NVCT
Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year
PremiumThe Fly
Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year
2M ago
NVCT
Strategic Pipeline Reprioritization and Promising Clinical Progress Drive Buy Rating for Nuvectis Pharma
PremiumRatings
Strategic Pipeline Reprioritization and Promising Clinical Progress Drive Buy Rating for Nuvectis Pharma
2M ago
NVCT
Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright
PremiumThe FlyNuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright
2M ago
NVCT
Strategic Focus on NXP900 Drives Buy Rating for Nuvectis Pharma
Premium
Ratings
Strategic Focus on NXP900 Drives Buy Rating for Nuvectis Pharma
2M ago
NVCT
Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study
Premium
The Fly
Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study
2M ago
NVCT
Promising Potential of NXP900 in Combination Therapy for Resistant Lung Cancer Justifies Buy Rating
PremiumRatings
Promising Potential of NXP900 in Combination Therapy for Resistant Lung Cancer Justifies Buy Rating
2M ago
NVCT
Promising Developments in Nuvectis Pharma’s NXP900 Boost Buy Rating
PremiumRatings
Promising Developments in Nuvectis Pharma’s NXP900 Boost Buy Rating
2M ago
NVCT
Nuvectis Pharma’s NXP900 shows positive drug interaction results in lung cancer
PremiumThe Fly
Nuvectis Pharma’s NXP900 shows positive drug interaction results in lung cancer
2M ago
NVCT
Nuvectis Pharma Approves Proposals at Annual Meeting
PremiumCompany Announcements
Nuvectis Pharma Approves Proposals at Annual Meeting
3M ago
8K
NVCT
Nuvectis Pharma Launches New $60M Stock Offering Program
PremiumCompany AnnouncementsNuvectis Pharma Launches New $60M Stock Offering Program
4M ago
8K
NVCT
Nuvectis Pharma Reports Q1 2025 Progress and Financials
Premium
Company Announcements
Nuvectis Pharma Reports Q1 2025 Progress and Financials
5M ago
NVCT
Promising Advancements and Financial Stability Justify Buy Rating for Nuvectis Pharma
Premium
Ratings
Promising Advancements and Financial Stability Justify Buy Rating for Nuvectis Pharma
5M ago
NVCT
Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year
PremiumThe Fly
Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year
5M ago
NVCT
Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies
PremiumRatings
Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies
5M ago
NVCT
Promising Developments in Nuvectis Pharma’s NXP900 Drive Buy Rating
PremiumRatings
Promising Developments in Nuvectis Pharma’s NXP900 Drive Buy Rating
5M ago
NVCT
Nuvectis Pharma price target raised to $15 from $11 at H.C. Wainwright
PremiumThe Fly
Nuvectis Pharma price target raised to $15 from $11 at H.C. Wainwright
5M ago
NVCT
Nuvectis Pharma initiated with a Buy at Maxim
PremiumThe FlyNuvectis Pharma initiated with a Buy at Maxim
6M ago
NVCT
Nuvectis Pharma initiated with a Buy at Laidlaw
Premium
The Fly
Nuvectis Pharma initiated with a Buy at Laidlaw
6M ago
NVCT
Nuvectis announces new publication of research study on NXP900, osimertinib
Premium
The Fly
Nuvectis announces new publication of research study on NXP900, osimertinib
7M ago
NVCT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >